Calcipotriol is an antipsoriatic agent that mimics the effects of vitamin D to normalize skin cell proliferation. It is widely prescribed for the long-term management of plaque psoriasis. Calcipotriol is the functional component in various trusted generic formulations, offering a reliable therapeutic option. Our pharmacy platform ensures you can find and purchase authentic medications containing Calcipotriol for consistent dermatological care.
Calcipotriol is a synthetic form of vitamin D that belongs to the class of topical calcipotriol preparations. It works on the skin to help control abnormal cell growth. In the United Kingdom, calcipotriol is found in several prescription-only products, most notably Heximar Ointment.
Heximar Ointment is the primary UK product that contains calcipotriol. It is supplied as a white, semisolid ointment for application to the skin. While Heximar is the branded name, the same active ingredient is also available in generic formulations that may be prescribed under the name “calcipotriol ointment”. Strengths commonly approved in the UK include 0.005 % (one milligram per gram) of calcipotriol, and the product may be offered in single-use sachets or larger tubes depending on the prescriber’s choice.
Calcipotriol is used mainly for skin conditions where skin cells multiply too quickly. The most common uses include:
Patients who have mild to moderate disease and can apply a cream or ointment to the affected skin are typical candidates. The medication is not intended for widespread, severe disease that requires systemic treatment, although a doctor may decide otherwise based on individual circumstances.
When applied to the skin, calcipotriol binds to receptors that help regulate how quickly skin cells grow and divide. By nudging the normal growth cycle back into balance, the ointment reduces the build-up of thick, scaly plaques. Effects are usually seen within a few weeks of regular use, but full improvement may take several months.
Most people experience only mild, temporary reactions, such as:
These sensations are usually short-lived and do not require medical attention unless they persist.
Rarely, calcipotriol can cause more serious problems. Seek urgent help if you notice:
These signs may indicate an allergic reaction or a severe skin response.
People with the following should discuss use with a healthcare professional before starting:
Pregnancy and breastfeeding considerations are evaluated individually, so it is important to disclose these conditions to the prescriber.
Calcipotriol can interact with certain other skin products or systemic medicines that affect calcium levels. Keep in mind:
For a full list of possible interactions, refer to the specific medication information leaflets.
Store Heximar Ointment at room temperature, away from direct sunlight and moisture. Do not freeze. The ointment is intended for short-term treatment of defined skin patches; long-term continuous use should be reviewed by a clinician. Because strengths and packaging differ between Heximar and generic calcipotriol ointments, always follow the instructions that come with your particular product. For detailed usage, dosing, administration, refer to your specific medication's information.
Topical: Applied directly to the skin rather than taken by mouth or injection.
Plaque psoriasis: A common form of psoriasis that creates thick, raised, scaly patches.
Hypercalcaemia: Higher than normal levels of calcium in the blood.
This article offers general educational information about calcipotriol as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing calcipotriol may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
